Cargando...
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
BACKGROUND/AIMS: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed, and a substantial number of patients need alternative treatment...
Guardado en:
| Publicado en: | Korean J Intern Med |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
The Korean Association of Internal Medicine
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4773721/ https://ncbi.nlm.nih.gov/pubmed/26874514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2015.024 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|